PDEX · STOCK
Pro-Dex Inc (PDEX.US)
Pro-Dex Snapshot
Pro-Dex designs, develops, and manufactures powered surgical instruments for orthopedic, thoracic, and craniomaxillofacial procedures — selling exclusively to medical device OEMs worldwide. This niche B2B focus delivers strong profitability on $0.1B TTM revenue: gross margins of 28%, operating margins of 18%, and ROE of 31%, fueled by low debt and efficient operations with just 179 employees. The Powered Surgical Instruments segment drives 85% of sales and accelerating growth. Pro-Dex holds a competitive edge through FDA approvals, patents, and OEM switching costs. But watch the key risk: heavy reliance on a handful of large customers could amplify revenue swings.
- Market cap
- $166.6M
- Revenue (TTM)
- $72.1M
- Gross margin
- 28.3%
- Operating margin
- 17.5%
- P/E (TTM)
- 15.24
- P/S
- 2.31
- EV/EBITDA
- 9.71
- Beta
- -0.11
- 52-week high
- $68.33
- 52-week low
- $23.47
- Employees
- 179
Pro-Dex at a Glance
Pro-Dex is a specialized medical device company that designs, develops, manufactures, and sells powered surgical instruments. These tools target orthopedic (bone-related), thoracic (chest), and craniomaxillofacial (skull and face) procedures, sold primarily to original equipment manufacturers (OEMs) around the world. This focus positions Pro-Dex in the Healthcare sector's Medical Instruments & Supplies industry. Key financials underscore its efficiency: TTM revenue stands at $0.1B with a $0.2B market cap and just 179 employees based in Irvine, California. Profitability shines with 28.3% gross margins, 17.5% operating margins, 30.9% ROE, negligible debt, and a beta of -0.11 indicating low market sensitivity. These metrics reveal a lean, high-return operation that punches above its weight — setting up a central tension between niche OEM leverage and customer concentration risks.…